Key Details
Price
$331.45Annual ROE
-92.18%Beta
0.80Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Oct 31, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
July 25, 2016Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in Madrigal (MDGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
There's a bright future ahead for this company.
Does Madrigal (MDGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:
Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval, positioning it as a foundational therapy for NASH with advanced fibrosis. Broad insurance coverage and allowance for non-invasive testing [NIT] enhance patient accessibility and Rezdiffra's adoption rate. Competition from Novo Nordisk's Semaglutide poses a market risk, but Rezdiffra's liver-specific mechanism offers a targeted advantage.
MDGL stock is up as the company reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Madrigal (MDGL) came out with a quarterly loss of $4.92 per share versus the Zacks Consensus Estimate of a loss of $6.94. This compares to loss of $5.34 per share a year ago.
CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced multiple resmetirom data presentations at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting, taking place from November 15-19, 2024 in San Diego.
Madrigal Pharmaceuticals' Rezdiffra, approved for NASH, shows strong early demand and revenue growth, making Q3 earnings a potential catalyst for stock movement. Despite steep Q2 losses, Madrigal's $1.1B cash reserves and strategic execution position Rezdiffra as the market leader in NASH/MASH. Analysts forecast substantial revenue growth and narrowing losses for Madrigal, with expectations of profitability within a few years.
CONSHOHOCKEN, Pa., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced the MAESTRO-NASH OUTCOMES trial evaluating resmetirom for the treatment of patients with compensated NASH cirrhosis has completed enrollment.
FAQ
- What is the primary business of Madrigal Pharmaceuticals?
- What is the ticker symbol for Madrigal Pharmaceuticals?
- Does Madrigal Pharmaceuticals pay dividends?
- What sector is Madrigal Pharmaceuticals in?
- What industry is Madrigal Pharmaceuticals in?
- What country is Madrigal Pharmaceuticals based in?
- When did Madrigal Pharmaceuticals go public?
- Is Madrigal Pharmaceuticals in the S&P 500?
- Is Madrigal Pharmaceuticals in the NASDAQ 100?
- Is Madrigal Pharmaceuticals in the Dow Jones?
- When was Madrigal Pharmaceuticals's last earnings report?
- When does Madrigal Pharmaceuticals report earnings?
- Should I buy Madrigal Pharmaceuticals stock now?